{"denoms":[{"counts":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"145"},{"groupId":"BG002","value":"217"}],"units":"Participants"}],"groups":[{"description":"Obinutuzumab 1000 milligrams (mg) intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6; and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"BG000","title":"Obinutuzumab"},{"description":"Zanubrutinib 160 mg twice a day orally with or without food and obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6, and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"BG001","title":"Zanubrutinib + Obinutuzumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.81","value":"62.9"},{"groupId":"BG001","spread":"11.98","value":"61.1"},{"groupId":"BG002","spread":"12.26","value":"61.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"109"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"108"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"176"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"35"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"139"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"47"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"31"}]}],"title":"Not Reported"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-Treat (ITT) analysis set includes all randomized participants."}